You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
常茂生物(00954.HK)中期淨利24.2萬元 同比減少98.41%
格隆匯 08-18 17:02

格隆匯8月18日丨常茂生物(00954.HK)公佈中期業績,截至2021年6月30日止六個月,公司實現收入2.4億元人民幣(下同),同比增長12.01%;公司股東應占利潤24.2萬元,同比減少98.41%;基本每股盈利0.000元。

2020年上半年常州濱江開發區政府對位於長江沿岸一公里企業做出規劃調整,致本集團主產品原料順酐於當年六月停產,停產順酐後全部外購至今。2021年上半年順酐市場價格持續上漲並維持高位,造成集團生產成本大幅增加;此外,順酐停產導致集團無法通過副產蒸汽獲益,同時需提高蒸汽外採數量,加蒸汽價格同比增長,進一步提高了產品生產成本,導致毛利率下降。

2021年上半年,全球新冠疫情捲土重來,自去年疫情爆發以來始終壓制國外市場需求,這對集團主要出口產品市場價格造成衝擊,導致毛利率下降。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account